CareMedi uses Silicon Labs wireless IoT technology to create a patch-based insulin pump

• Compared with traditional patch pumps, the drug capacity is increased by 1.5 times.
  

• It is 11mm thick and weighs 20g, making it comfortable to wear.

• The IP48-rated waterproof design allows you to comfortably carry out daily activities and various outdoor activities.

The world of diabetes management is undergoing a transformation, driven by surging demand for safe, reliable, wireless continuous glucose monitoring (CGM) devices that can seamlessly integrate into patients' lives and advances in patch-based insulin pump technology. As the field of connected health devices continues to grow, CareMedi, an innovative medical Internet of Things (IoT) company based in South Korea, also sees an opportunity to improve the insulin pump market.

Although the development of insulin injection devices has made great progress compared to the first insulin pump introduced in the late 1970s, many traditional patch-type insulin pumps often still fail to solve the long-term problems faced by diabetic patients, such as inaccurate insulin injection, bulky design, high energy consumption, and high cost.

This is where CareMedi's CareLevo comes in, a revolutionary wearable design that promises to redefine the usage model for insulin pump users. Controlled by an easy-to-use smartphone app, CareLevo is the world's first patch-type insulin pump with a 3 milliliter (ml) drug reservoir that achieves drug injection accuracy within ±5% using an ultra-small, low-power electroosmotic pump developed using CareMedi's original PEOP electroosmotic pump technology. The electroosmotic pump is driven by applying voltage across a porous membrane. This breakthrough technology prioritizes accurate and correct insulin injection, longer use cycles, higher economic efficiency, and improved ease of use, which can significantly improve the quality of life of people with diabetes.

Silicon Labs’ Important Role in Connected Health IoT Solutions

CareMedi recently integrated Silicon Labs' versatile BG22 Bluetooth system-on-chip (SoC) into its CareLevo device, making it the lightest and thinnest wirelessly controlled dosing pump system on the market. BG22 played a crucial role in helping CareLevo improve battery performance by 30%. With low-power technology, this thin and light wearable pump system can inject 3 ml (300 units) of medication within a power consumption range of 3 milliamp hours (mA•h).

Many connected health device providers, such as CareMedi, rely on Silicon Labs’ IoT solutions to develop the next generation of innovative medical devices because Silicon Labs offers the lowest power Bluetooth Low Energy SoC on the market and the smallest 4mm x 4mm form factor for connected health applications. When CareMedi integrated the BG22, Silicon Labs was able to help provide the design resources and timely technical support needed.

As a global leader in the Internet of Things, Silicon Labs' high transmit power and superior receiver sensitivity help ensure reliable connections and maintain high data rates, while reducing retransmissions to increase channel capacity and save energy. Silicon Labs is a key partner to medical device companies working to make healthcare technology more accessible and improve the lives of people around the world.

CareMedi unlocks the potential of wireless insulin pump devices

CareMedi's CareLevo is equipped with a 3 ml insulin patch pump based on CareMedi's core technology, which can efficiently provide accurate insulin injections through a smartphone app. The drug capacity of this innovative electroosmotic pump is 1.5 times that of a traditional patch pump (2 ml). The longer usage cycle makes the device more cost-effective and very beneficial to insulin pump users.

In addition, unlike existing insulin patches that are bulky and uncomfortable, CareLevo has a thin and lightweight design with a thickness of 11 mm and a weight of 20 grams, which is more comfortable in daily life. The CareLevo device also adopts a waterproof design, which supports insulin pump users to enjoy leisure activities, outdoor activities, showering, swimming and other activities while wearing the product. This feature allows the device to be easily attached to the arm or abdomen, while comfortably performing various daily activities, which can significantly improve the quality of life of diabetic patients.

In addition, CareLevo's app and website can support insulin pump users to conveniently control their blood sugar levels. This advantage not only brings convenience to users, but also opens up a broader picture in the field of continuous glucose monitoring, because healthcare providers will be able to easily obtain blood sugar readings and insulin injection history to determine the patient's insulin dosage.

The Future of Smart Insulin Pump Solutions

Silicon Labs' BG22 plays an important role in driving innovation in insulin pump devices and addressing key challenges in the connected health industry, including inaccurate insulin injections, uncomfortable and impractical designs, low energy efficiency, and high costs. Through close collaboration with partners such as CareMedi, Silicon Labs is able to support the development of easy-to-use, reliable, and accurate connected health devices for insulin injection. CareMedi's CareLevo insulin patch is currently under development and is scheduled to be launched in South Korea in the second half of 2024. The company plans to obtain U.S. FDA approval in 2025 and expects to obtain European CE certification in 2026.

Silicon Labs is proud to help improve the quality of life for people with diabetes by providing solutions for easy-to-use, smart insulin pump devices. We look forward to further advancing the Internet of Medical Things.